Brokerages Set Immuneering Corporation (NASDAQ:IMRX) PT at $16.50

Shares of Immuneering Corporation (NASDAQ:IMRX) have been assigned an average rating of “Moderate Buy” from the seven analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $16.50.

Several research analysts recently issued reports on the company. Wall Street Zen cut shares of Immuneering from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Chardan Capital reissued a “buy” rating and set a $20.00 price objective on shares of Immuneering in a report on Thursday, November 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research report on Monday, December 29th.

Immuneering Price Performance

IMRX stock opened at $4.99 on Thursday. The firm has a market cap of $322.20 million, a price-to-earnings ratio of -2.80 and a beta of 0.46. Immuneering has a twelve month low of $1.10 and a twelve month high of $10.08. The business’s fifty day simple moving average is $5.37 and its two-hundred day simple moving average is $6.04.

Insider Activity

In other Immuneering news, Director Peter Feinberg acquired 20,000 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was acquired at an average cost of $4.35 per share, for a total transaction of $87,000.00. Following the completion of the transaction, the director directly owned 135,441 shares of the company’s stock, valued at $589,168.35. This represents a 17.32% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Thomas J. Schall bought 21,645 shares of Immuneering stock in a transaction dated Thursday, January 15th. The shares were acquired at an average cost of $4.67 per share, with a total value of $101,082.15. Following the completion of the purchase, the director owned 74,530 shares in the company, valued at approximately $348,055.10. This trade represents a 40.93% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have purchased 51,819 shares of company stock worth $234,472. 22.90% of the stock is owned by corporate insiders.

Institutional Trading of Immuneering

Several large investors have recently made changes to their positions in the company. Jane Street Group LLC acquired a new stake in shares of Immuneering during the 1st quarter worth approximately $32,000. China Universal Asset Management Co. Ltd. acquired a new stake in Immuneering during the third quarter worth $35,000. Future Financial Wealth Managment LLC purchased a new stake in Immuneering in the third quarter valued at $35,000. Kingsview Wealth Management LLC purchased a new stake in Immuneering in the second quarter valued at $47,000. Finally, SummitTX Capital L.P. acquired a new position in shares of Immuneering in the 4th quarter valued at $69,000. 67.65% of the stock is currently owned by hedge funds and other institutional investors.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.